{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T04:45:11Z","timestamp":1792471511996,"version":"4.5.0"},"reference-count":118,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T00:00:00Z","timestamp":1767398400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007533","name":"Kobayashi Foundation for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007533","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22K09449"],"award-info":[{"award-number":["22K09449"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22KK0135"],"award-info":[{"award-number":["22KK0135"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.urolonc.2025.110987","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T22:16:12Z","timestamp":1769552172000},"page":"110987","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Molecular pathology of rare histologic variants and treatment-resistant lineages of prostate cancer"],"prefix":"10.1016","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6656-4261","authenticated-orcid":false,"given":"Ryuta","family":"Watanabe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyoshi","family":"Miura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadahiko","family":"Kikugawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Saika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Haffner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter S.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.urolonc.2025.110987_bib0001","first-page":"26","article-title":"Updates of prostate cancer from the 2022 World Health Organization classification of the urinary and male genital tumors","volume":"3","author":"Guo","year":"2023","journal-title":"J Clin Transl Pathol"},{"key":"10.1016\/j.urolonc.2025.110987_bib0002","doi-asserted-by":"crossref","unstructured":"Surintrspanont J, Zhou M. Prostate pathology: what is new in the 2022 WHO classification of urinary and male genital tumors? Pathologica. 2022;115(1):41\u201356. doi: 10.32074\/1591-951X-822.","DOI":"10.32074\/1591-951X-822"},{"key":"10.1016\/j.urolonc.2025.110987_bib0003","doi-asserted-by":"crossref","unstructured":"Comp\u00e9rat E, Kl\u00e4ger J, Rioux-Leclercq N, Oszwald A, Wasinger G. Cribriform versus intraductal: how to determine the difference. Cancers (Basel). 2024;16(11):2002. doi: 10.3390\/cancers16112002.","DOI":"10.3390\/cancers16112002"},{"issue":"3","key":"10.1016\/j.urolonc.2025.110987_bib0004","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/s41391-024-00866-4","article-title":"Rare histological prostate cancer subtypes: cancer-specific and other-cause mortality","volume":"28","author":"Siech","year":"2025","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"8","key":"10.1016\/j.urolonc.2025.110987_bib0005","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1097\/PAS.0000000000001728","article-title":"ISUP consensus definition of cribriform pattern prostate cancer","volume":"45","author":"van der Kwast","year":"2021","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.urolonc.2025.110987_bib0006","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/j.1464-410X.2011.10520.x","article-title":"Incidence and outcomesof ductal carcinoma of the prostate in the USA: analysis of datafrom the surveillance, epidemiology, and end results program","volume":"109","author":"Meeks","year":"2012","journal-title":"BJU Int"},{"issue":"2","key":"10.1016\/j.urolonc.2025.110987_bib0007","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1158\/1541-7786.MCR-18-0440","article-title":"Genetic and epigenetic determinants of aggressiveness in cribriform carcinoma of the prostate","volume":"17","author":"Elfandy","year":"2019","journal-title":"Mol Cancer Res"},{"issue":"10","key":"10.1016\/j.urolonc.2025.110987_bib0008","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1038\/modpathol.2010.120","article-title":"TMPRSS2-ERG gene fusion is associated with low Gleason scores and not with high-grade morphological features","volume":"23","author":"Fine","year":"2010","journal-title":"Mod Pathol"},{"issue":"1","key":"10.1016\/j.urolonc.2025.110987_bib0009","doi-asserted-by":"crossref","first-page":"6036","DOI":"10.1038\/s41467-022-33780-1","article-title":"Single cell analysis of cribriform prostate cancer reveals cell intrinsic and tumor microenvironmental pathways of aggressive disease","volume":"13","author":"Wong","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.urolonc.2025.110987_bib0010","first-page":"337","article-title":"Optimizing the diagnosis and management of ductal prostate cancer","volume":"18","author":"Ranasinghe","year":"2021","journal-title":"Nat RevUrol"},{"issue":"3","key":"10.1016\/j.urolonc.2025.110987_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2018.06.039","article-title":"Genomic hallmarks and structural variation in metastatic prostate cancer","volume":"174","author":"Quigley","year":"2018","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.urolonc.2025.110987_bib0012","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.18632\/oncotarget.1802","article-title":"Androgen receptor splice variants activating the full-length receptor in mediating resistance to androgen-directed therapy","volume":"5","author":"Cao","year":"2014","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.urolonc.2025.110987_bib0013","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.eururo.2020.05.009","article-title":"Transcriptomic heterogeneity of Gleason grade group 5 prostate cancer","volume":"78","author":"Kishan","year":"2020","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2025.110987_bib0014","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0022-5347(17)60451-8","article-title":"Intraductal carcinoma of the prostate gland","volume":"109","author":"Rhamy","year":"1973","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2025.110987_bib0015","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/(SICI)1097-0045(20000401)43:1<11::AID-PROS3>3.0.CO;2-B","article-title":"Patterns of differentiation and proliferation in intraductal carcinoma of the prostate: significance for cancer progression","volume":"43","author":"Cohen","year":"2000","journal-title":"Prostate"},{"issue":"10","key":"10.1016\/j.urolonc.2025.110987_bib0016","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1097\/PAS.0000000000000465","article-title":"Prostate biopsy specimens with gleason 3+3=6 and intraductal carcinoma: radical prostatectomy findings and clinical outcomes","volume":"39","author":"Khani","year":"2015","journal-title":"Am J Surg Pathol"},{"issue":"10","key":"10.1016\/j.urolonc.2025.110987_bib0017","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.5858\/arpa.2015-0206-RA","article-title":"Intraductal carcinoma of the prostate: morphologic features, differential diagnoses, significance, and reporting practices","volume":"139","author":"Magers","year":"2015","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.urolonc.2025.110987_bib0018","article-title":"Treatment outcomes and comparative survival analysis of intraductal carcinoma of the prostate","author":"Stamey","year":"2025","journal-title":"Int Urol Nephrol"},{"issue":"7","key":"10.1016\/j.urolonc.2025.110987_bib0019","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1111\/cas.15392","article-title":"Clinical significance of IDC-P as predictive factor after intensity-modulated radiation therapy","volume":"113","author":"Aizawa","year":"2022","journal-title":"Cancer Sci"},{"issue":"4","key":"10.1016\/j.urolonc.2025.110987_bib0020","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s10147-025-02707-3","article-title":"Prospective observational study on the relationships between genetic alterations and survival in Japanese patients with metastatic castration-sensitive prostate cancer: the impact of IDC-P","volume":"30","author":"Kato","year":"2025","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.urolonc.2025.110987_bib0021","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/iju.12657","article-title":"Intraductal carcinoma of the prostate: a comprehensive and updated review","volume":"22","author":"Tsuzuki","year":"2015","journal-title":"Int J Urol"},{"key":"10.1016\/j.urolonc.2025.110987_bib0022","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/PAT.0b013e3283653322","article-title":"Intraductal carcinoma of the prostate: the whole story","volume":"45","author":"Zhou","year":"2013","journal-title":"Pathology"},{"key":"10.1016\/j.urolonc.2025.110987_bib0023","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s00428-019-02544-6","article-title":"Intraductal carcinoma of the prostate: a critical re-appraisal","volume":"474","author":"Varma","year":"2019","journal-title":"Virchows Arch"},{"issue":"5","key":"10.1016\/j.urolonc.2025.110987_bib0024","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.eururo.2022.07.002","article-title":"The 2022 World Health Organization classification of tumors of the urinary system and male genital organs-Part B: prostate and urinary tract tumors","volume":"82","author":"Netto","year":"2022","journal-title":"Eur Urol"},{"issue":"7","key":"10.1016\/j.urolonc.2025.110987_bib0025","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/gcc.20560","article-title":"Chromosomal imbalances, loss of heterozygosity, and immunohistochemical expression of TP53, RB1, and PTEN in intraductal cancer, intraepithelial neoplasia, and invasive adenocarcinoma of the prostate","volume":"47","author":"Bettendorf","year":"2008","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.urolonc.2025.110987_bib0026","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms13671","article-title":"Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories","volume":"8","author":"Taylor","year":"2017","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.urolonc.2025.110987_bib0027","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.eururo.2014.08.007","article-title":"Patient-derived xenografts reveal that intraductal carcinoma of the prostate is a prominent pathology in BRCA2 mutation carriers with prostate cancer and correlates with poor prognosis","volume":"67","author":"Risbridger","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2025.110987_bib0028","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/path.4628","article-title":"Molecular evidence that invasive adenocarcinoma can mimic prostatic intraepithelial neoplasia (PIN) and intraductal carcinoma through retrograde glandular colonization","volume":"238","author":"Haffner","year":"2016","journal-title":"J Pathol"},{"key":"10.1016\/j.urolonc.2025.110987_bib0029","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ejca.2021.01.027","article-title":"Association between BRCA2 alterations and intraductal and cribriform histologies in prostate cancer","volume":"147","author":"Lozano","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.urolonc.2025.110987_bib0030","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.humpath.2024.01.005","article-title":"Histologic patterns in prostatic adenocarcinoma are not predictive of mutations in the homologous recombination repair pathway","volume":"144","author":"Mahlow","year":"2024","journal-title":"Hum Pathol"},{"issue":"9","key":"10.1016\/j.urolonc.2025.110987_bib0031","doi-asserted-by":"crossref","first-page":"4818","DOI":"10.3390\/ijms25094818","article-title":"Saika T unveiling the genomic landscape of intraductal carcinoma of the prostate using spatial gene expression analysis","volume":"25","author":"Watanabe","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.urolonc.2025.110987_bib0032","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.eururo.2018.12.036","article-title":"Molecular hallmarks of multiparametric magnetic resonance imaging visibility in prostate cancer","volume":"76","author":"Houlahan","year":"2019","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2025.110987_bib0033","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/his.15551","article-title":"Spatial transcriptomics of intraductal carcinoma of the prostate","volume":"87","author":"Takahara","year":"2025","journal-title":"Histopathology"},{"key":"10.1016\/j.urolonc.2025.110987_bib0034","article-title":"Spatial characteristics of intraductal carcinoma of the prostate","author":"Dupuis","year":"2025","journal-title":"Prostate"},{"key":"10.1016\/j.urolonc.2025.110987_bib0035","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.humpath.2009.08.010","article-title":"Any proportionof ductal adenocarcinoma in radical prostatectomy specimenspredicts extraprostatic extension","volume":"41","author":"Samaratunga","year":"2010","journal-title":"Hum Pathol"},{"key":"10.1016\/j.urolonc.2025.110987_bib0036","doi-asserted-by":"crossref","unstructured":"Tu SM, Reyes A, Maa A, Bhowmick D, Pisters LL, Pettaway CA, et al. Prostate carcinoma with testicular or penile metastases. clinical, pathologic, and immunohistochemical features. Cancer. 2002;94(10):2610\u20137. doi: 10.1002\/cncr.10546.","DOI":"10.1002\/cncr.10546"},{"issue":"2","key":"10.1016\/j.urolonc.2025.110987_bib0037","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/his.12382","article-title":"Diagnostic criteria for ductal adenocarcinoma of the prostate: interobserver variability among 20 expert uropathologists","volume":"65","author":"Seipel","year":"2014","journal-title":"Histopathology"},{"issue":"1","key":"10.1016\/j.urolonc.2025.110987_bib0038","first-page":"50","article-title":"The update of prostatic ductal adenocarcinoma","volume":"28","author":"Liu","year":"2016","journal-title":"Chin J Cancer Res"},{"key":"10.1016\/j.urolonc.2025.110987_bib0039","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.euf.2017.12.003","article-title":"Integrative genomic analysisof coincident cancer foci implicates CTNNB1 and PTEN alter-ations in ductal prostate cancer","volume":"5","author":"Gillard","year":"2019","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.urolonc.2025.110987_bib0040","article-title":"Genomic characterization of prostatic ductal adenocarcinoma identifiesa high prevalence of DNA repair gene mutations","volume":"3","author":"Schweizer","year":"2019","journal-title":"JCO PrecisOncol"},{"key":"10.1016\/j.urolonc.2025.110987_bib0041","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.humpath.2017.04.015","article-title":"Genetic profile of duc-tal adenocarcinoma of the prostate","volume":"69","author":"Seipel","year":"2017","journal-title":"Hum Pathol"},{"issue":"50","key":"10.1016\/j.urolonc.2025.110987_bib0042","doi-asserted-by":"crossref","first-page":"82504","DOI":"10.18632\/oncotarget.12697","article-title":"Mismatch repair deficiency may be common in ductal adenocarcinoma of the prostate","volume":"7","author":"Schweizer","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.urolonc.2025.110987_bib0043","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.eururo.2020.11.015","article-title":"Ductal prostatecancers demonstrate poor outcomes with conventional therapies","volume":"79","author":"Ranasinghe","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2025.110987_bib0044","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1158\/0008-5472.CAN-17-3006","article-title":"Inhibition of the Wnt\/beta-cateninpathway overcomes resistance to enzalutamide in castration-resistant prostate cancer","volume":"78","author":"Zhang","year":"2018","journal-title":"Cancer Res"},{"issue":"9","key":"10.1016\/j.urolonc.2025.110987_bib0045","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1038\/modpathol.2009.79","article-title":"Characterization of ETS gene aberrations in select histologic variants of prostate carcinoma","volume":"22","author":"Han","year":"2009","journal-title":"Mod Pathol"},{"issue":"3","key":"10.1016\/j.urolonc.2025.110987_bib0046","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/modpathol.2008.236","article-title":"TMPRSS2-ERG gene fusions are infrequent in prostatic ductal adenocarcinomas","volume":"22","author":"Lotan","year":"2009","journal-title":"Mod Pathol"},{"issue":"12","key":"10.1016\/j.urolonc.2025.110987_bib0047","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1002\/pros.23383","article-title":"Ductal adenocarcinoma of the prostate: clinical and biological profiles","volume":"77","author":"Vinceneux","year":"2017","journal-title":"Prostate"},{"issue":"14","key":"10.1016\/j.urolonc.2025.110987_bib0048","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1002\/pros.23042","article-title":"PTEN loss and ERG protein expression are infrequent in prostatic ductal adenocarcinomas and concurrent acinar carcinomas","volume":"75","author":"Morais","year":"2015","journal-title":"Prostate"},{"issue":"6","key":"10.1016\/j.urolonc.2025.110987_bib0049","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2025.100743","article-title":"Prostate ductal Adenocarcinoma revisited: clinicopathological and genomic characterization identifies heterogenous group of diseases with implications for patient management","volume":"38","author":"Cai","year":"2025","journal-title":"Mod Pathol"},{"key":"10.1016\/j.urolonc.2025.110987_bib0050","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.semcancer.2022.05.007","article-title":"Molecular mechanisms underlying the development of neuroendocrine prostate cancer","volume":"86","author":"Liu","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.urolonc.2025.110987_bib0051","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ejca.2019.08.011","article-title":"Clinical features of neuroendocrine prostate cancer","volume":"121","author":"Conteduca","year":"2019","journal-title":"Eur J Cancer Oxf Engl"},{"issue":"2","key":"10.1016\/j.urolonc.2025.110987_bib0052","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11912-020-01003-9","article-title":"Clinical and biological features of neuroendocrine prostate cancer","volume":"23","author":"Yamada","year":"2021","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.urolonc.2025.110987_bib0053","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/bco2.212","article-title":"Genomic alterations in neuroendocrine prostate cancer: a systematic review and meta-analysis","volume":"4","author":"Chen","year":"2023","journal-title":"BJUI Compass"},{"issue":"23","key":"10.1016\/j.urolonc.2025.110987_bib0054","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.185952","article-title":"ASCL1 regulates and cooperates with FOXA2 to drive terminal neuroendocrine phenotype in prostate cancer","volume":"9","author":"Nouruzi","year":"2024","journal-title":"JCI Insight"},{"issue":"24","key":"10.1016\/j.urolonc.2025.110987_bib0055","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2017.77.6880","article-title":"Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study","volume":"36","author":"Aggarwal","year":"2018","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.urolonc.2025.110987_bib0056","doi-asserted-by":"crossref","first-page":"11428","DOI":"10.1073\/pnas.1902651116","article-title":"Genomic correlates of clinical outcome in advanced prostate cancer","volume":"116","author":"Abida","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"10.1016\/j.urolonc.2025.110987_bib0057","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.ccell.2017.09.003","article-title":"Androgen receptor pathway-independent prostate cancer is sustained through FGF signaling","volume":"32","author":"Bluemn","year":"2017","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.urolonc.2025.110987_bib0058","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1158\/2159-8290.CD-11-0130","article-title":"Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets","volume":"1","author":"Beltran","year":"2011","journal-title":"Cancer Discov"},{"issue":"10","key":"10.1016\/j.urolonc.2025.110987_bib0059","doi-asserted-by":"crossref","first-page":"8955","DOI":"10.3390\/ijms24108955","article-title":"Spatial gene expression analysis reveals characteristic gene expression patterns of de novo neuroendocrine prostate cancer coexisting with androgen receptor pathway prostate cancer","volume":"24","author":"Watanabe","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"10","key":"10.1016\/j.urolonc.2025.110987_bib0060","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1007\/s00432-024-05983-0","article-title":"Unraveling molecular characteristics and tumor microenvironment dynamics of neuroendocrine prostate cancer","volume":"150","author":"Heimd\u00f6rfer","year":"2024","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.urolonc.2025.110987_bib0061","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/s41419-023-05836-7","article-title":"CHRM4\/AKT\/MYCN upregulates interferon alpha-17 in the tumor microenvironment to promote neuroendocrine differentiation of prostate cancer","volume":"14","author":"Wen","year":"2023","journal-title":"Cell Death Dis"},{"issue":"6410","key":"10.1016\/j.urolonc.2025.110987_bib0062","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.aat5749","article-title":"Reprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineage","volume":"362","author":"Park","year":"2018","journal-title":"Science"},{"issue":"15","key":"10.1016\/j.urolonc.2025.110987_bib0063","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1158\/1078-0432.CCR-22-3743","article-title":"Immunogenomic landscape of neuroendocrine prostate cancer","volume":"29","author":"Bhinder","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.urolonc.2025.110987_bib0064","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1097\/PAS.0000000000000208","article-title":"Proposed morphologic classification of prostate cancer with neuroendocrine differentiation","volume":"38","author":"Epstein","year":"2014","journal-title":"Am J Surg Pathol"},{"issue":"6","key":"10.1016\/j.urolonc.2025.110987_bib0065","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1097\/00000478-200606000-00005","article-title":"Small cell carcinoma of the prostate: an immunohistochemical study","volume":"30","author":"Yao","year":"2006","journal-title":"Am J Surg Pathol"},{"issue":"7","key":"10.1016\/j.urolonc.2025.110987_bib0066","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.ctrv.2015.05.003","article-title":"The hallmarks of castration-resistant prostate cancers","volume":"41","author":"Katsogiannou","year":"2015","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"10.1016\/j.urolonc.2025.110987_bib0067","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s42003-020-01549-1","article-title":"Nerve growth factor interacts with CHRM4 and promotes neuroendocrine differentiation of prostate cancer and castration resistance","volume":"4","author":"Chen","year":"2021","journal-title":"Commun Biol"},{"issue":"3","key":"10.1016\/j.urolonc.2025.110987_bib0068","doi-asserted-by":"crossref","first-page":"320","DOI":"10.5858\/arpa.2019-0434-RA","article-title":"Morphologic spectrum of neuroendocrine tumors of the prostate: an updated review","volume":"144","author":"Hu","year":"2020","journal-title":"Arch Pathol Lab Med"},{"issue":"3","key":"10.1016\/j.urolonc.2025.110987_bib0069","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1158\/1078-0432.CCR-24-2061","article-title":"Framework for the pathology workup of metastatic castration-resistant prostate cancer biopsies","volume":"31","author":"Haffner","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.urolonc.2025.110987_bib0070","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.eururo.2007.07.039","article-title":"Prostate carcinoma: atrophy or not atrophy that is the question","volume":"52","author":"Aggarwal","year":"2007","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2025.110987_bib0071","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.path.2024.10.001","article-title":"Molecular landscape of aggressive histologic subtypes of localized prostate cancer","volume":"18","author":"Ding","year":"2025","journal-title":"Surg Pathol Clin"},{"issue":"1","key":"10.1016\/j.urolonc.2025.110987_bib0072","doi-asserted-by":"crossref","first-page":"5775","DOI":"10.1038\/s41467-021-26042-z","article-title":"Subtype heterogeneity and epigenetic convergence in neuroendocrine prostate cancer","volume":"12","author":"Cejas","year":"2021","journal-title":"Nat Commun"},{"issue":"13","key":"10.1016\/j.urolonc.2025.110987_bib0073","doi-asserted-by":"crossref","first-page":"7740","DOI":"10.1093\/nar\/gkae547","article-title":"ONECUT2 acts as a lineage plasticity driver in adenocarcinoma as well as neuroendocrine variants of prostate cancer","volume":"52","author":"Qian","year":"2024","journal-title":"Nucleic Acids Res"},{"issue":"7","key":"10.1016\/j.urolonc.2025.110987_bib0074","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nrg2100","article-title":"Chromatin crosstalk in development and disease: lessons from REST","volume":"8","author":"Ooi","year":"2007","journal-title":"Nat Rev Genet"},{"issue":"7","key":"10.1016\/j.urolonc.2025.110987_bib0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2022.104576","article-title":"Single-cell transcriptional regulation and genetic evolution of neuroendocrine prostate cancer","volume":"25","author":"Wang","year":"2022","journal-title":"iScience"},{"key":"10.1016\/j.urolonc.2025.110987_bib0076","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.ccell.2022.10.011","article-title":"FOXA2 Drives lineage plasticity and KIT pathway activation in neuroendocrine prostate cancer","volume":"40","author":"Han","year":"2022","journal-title":"Cancer Cell"},{"issue":"484","key":"10.1016\/j.urolonc.2025.110987_bib0077","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav0891","article-title":"Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer","volume":"11","author":"Puca","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.urolonc.2025.110987_bib0078","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1158\/1535-7163.MCT-20-0848","article-title":"PARP and CDK4\/6 inhibitor combination therapy induces apoptosis and suppresses neuroendocrine differentiation in prostate cancer","volume":"20","author":"Wu","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.urolonc.2025.110987_bib0079","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.5012","article-title":"Phase 1b study of tarlatamab in de novo or treatment-emergent neuroendocrine prostate cancer (NEPC)","volume":"42","author":"Aggarwal","year":"2024","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.urolonc.2025.110987_bib0080","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/s41391-021-00332-5","article-title":"Clinical considerations for the management of androgen indifferent prostate cancer","volume":"24","author":"Berchuck","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"6","key":"10.1016\/j.urolonc.2025.110987_bib0081","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1158\/1078-0432.CCR-15-1259","article-title":"Combined tumor suppressor defects characterize clinically defined aggressive variant prostate cancers","volume":"22","author":"Aparicio","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2025.110987_bib0082","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.cell.2013.11.012","article-title":"Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade","volume":"155","author":"Arora","year":"2013","journal-title":"Cell"},{"issue":"19","key":"10.1016\/j.urolonc.2025.110987_bib0083","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1158\/1078-0432.CCR-13-3271","article-title":"Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy","volume":"20","author":"Taube","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.urolonc.2025.110987_bib0084","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.euo.2018.09.014","article-title":"Mannose receptor-positive macrophage infiltration correlates with prostate cancer onset and metastatic castration-resistant disease","volume":"2","author":"Zarif","year":"2019","journal-title":"Eur Urol Oncol"},{"issue":"6320","key":"10.1016\/j.urolonc.2025.110987_bib0085","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1126\/science.aah4307","article-title":"SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer","volume":"355","author":"Mu","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.urolonc.2025.110987_bib0086","doi-asserted-by":"crossref","first-page":"697e705","DOI":"10.1097\/01.pas.0000213395.42075.86","article-title":"Basal cell carcinoma of the prostate: a clinicopathologic study of 29 cases","volume":"31","author":"Ali","year":"2007","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.urolonc.2025.110987_bib0087","doi-asserted-by":"crossref","first-page":"1289e","DOI":"10.1097\/01.pas.0000138180.95581.e1","article-title":"Basal cell proliferations of the prostate other than usual basal cell hyperplasia: a clinicopathologic study of 23 cases, including four carcinomas, with a proposed classification","volume":"28","author":"McKenney","year":"2004","journal-title":"Am J Surg Pathol"},{"issue":"12","key":"10.1016\/j.urolonc.2025.110987_bib0088","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1097\/00000478-200312000-00004","article-title":"Adenoid cystic\/basal cell carcinoma of the prostate: clinicopathologic findings in 19 cases","volume":"27","author":"Iczkowski","year":"2003","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.urolonc.2025.110987_bib0089","doi-asserted-by":"crossref","first-page":"859","DOI":"10.3389\/fonc.2020.00859","article-title":"An unusual case of metastatic basal cell carcinoma of the prostate: a case report and literature review","volume":"10","author":"Dong","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.urolonc.2025.110987_bib0090","doi-asserted-by":"crossref","first-page":"1345e1349","DOI":"10.1111\/j.1464-410X.2007.06857.x","article-title":"Basal cell carcinoma of the prostate: current concepts","volume":"99","author":"Ayyathurai","year":"2007","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2025.110987_bib0091","doi-asserted-by":"crossref","first-page":"1447e1450","DOI":"10.1016\/S0046-8177(98)90014-4","article-title":"Distinction of basaloid carcinoma of the prostate from benign basal cell lesions by using immunohistochemistry for bcl-2 and Ki-67","volume":"29","author":"Yang","year":"1998","journal-title":"Hum Pathol"},{"key":"10.1016\/j.urolonc.2025.110987_bib0092","doi-asserted-by":"crossref","first-page":"174e183","DOI":"10.1002\/path.4186","article-title":"Nucleotide resolution analysis of TMPRSS2and ERG rearrangements in prostate cancer","volume":"230","author":"Weier","year":"2013","journal-title":"J Pathol"},{"issue":"1","key":"10.1016\/j.urolonc.2025.110987_bib0093","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.eururo.2016.02.028","article-title":"The 2016 WHO classification of tumours of the urinary system and male genital organs-part B: prostate and bladder tumours","volume":"70","author":"Humphrey","year":"2016","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2025.110987_bib0094","first-page":"130","article-title":"The pathology of unusual subtypes of prostate cancer","volume":"28","author":"Li","year":"2016","journal-title":"Chin J Cancer Res"},{"issue":"3","key":"10.1016\/j.urolonc.2025.110987_bib0095","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.3390\/curroncol29030152","article-title":"Adenoid cystic carcinoma\/basal cell carcinoma of the prostate: overview and update on rare prostate cancer subtypes","volume":"29","author":"Cozzi","year":"2022","journal-title":"Curr Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2025.110987_bib0096","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ajpath.2022.09.010","article-title":"Genomic characterization of prostatic basal cell carcinoma","volume":"193","author":"Low","year":"2023","journal-title":"Am J Pathol"},{"issue":"6","key":"10.1016\/j.urolonc.2025.110987_bib0097","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.prp.2011.01.012","article-title":"Adenoid cystic carcinoma of the prostate: case report on a rare entity and review of the literature","volume":"207","author":"Ahuja","year":"2011","journal-title":"Pathol Res Pract"},{"issue":"3","key":"10.1016\/j.urolonc.2025.110987_bib0098","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1158\/1078-0432.CCR-20-1192","article-title":"Proteogenomic analysis of salivary adenoid cystic carcinomas defines molecular subtypes and identifies therapeutic targets","volume":"27","author":"Ferrarotto","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.urolonc.2025.110987_bib0099","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/S0022-5347(17)57013-5","article-title":"Squamous cell carcinoma of the prostate: report of 2 cases and review of the literature","volume":"121","author":"Mott","year":"1979","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2025.110987_bib0100","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/iju5.12466","article-title":"Squamous cell carcinoma of the prostate with SMARCA4 alteration in a Japanese patient","volume":"5","author":"Kaneko","year":"2022","journal-title":"IJU Case Rep"},{"key":"10.1016\/j.urolonc.2025.110987_bib0101","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.1012005","article-title":"Endocrine and paracrine characteristics of neuroendocrine prostate cancer","volume":"13","author":"Arman","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"10.1016\/j.urolonc.2025.110987_bib0102","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/iju5.12824","article-title":"A case of testicular dysgenesis syndrome with squamous cell carcinoma of the prostate harboring a CDK12 mutation","volume":"8","author":"Murata","year":"2025","journal-title":"IJU Case Rep"},{"issue":"1","key":"10.1016\/j.urolonc.2025.110987_bib0103","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12920-022-01178-z","article-title":"Castration-resistant prostate cancer patient presenting with whole genome doubling with CDK-12 mutation","volume":"15","author":"Baba","year":"2022","journal-title":"BMC Med Genomics"},{"issue":"5","key":"10.1016\/j.urolonc.2025.110987_bib0104","doi-asserted-by":"crossref","first-page":"5265","DOI":"10.1002\/cam4.5333","article-title":"The prevalence of gene mutations in homologous recombination repair pathways in Japanese patients with metastatic castration-resistant prostate cancer in real-world clinical practice: the multi-institutional observational ZENSHIN study","volume":"12","author":"Uemura","year":"2023","journal-title":"Cancer Med"},{"issue":"10","key":"10.1016\/j.urolonc.2025.110987_bib0105","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1111\/j.1464-410X.2008.08074.x","article-title":"Rare and unusual histological variants of prostatic carcinoma: clinical significance","volume":"102","author":"Mazzucchelli","year":"2008","journal-title":"BJU Int"},{"issue":"6","key":"10.1016\/j.urolonc.2025.110987_bib0106","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1111\/his.12493","article-title":"Sarcomatoid carcinoma of the prostate: ERG fluorescence in-situ hybridization confirms epithelial origin","volume":"66","author":"Rodrigues","year":"2015","journal-title":"Histopathology"},{"issue":"2","key":"10.1016\/j.urolonc.2025.110987_bib0107","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/cncr.22372","article-title":"Prostate cancer progression in the presence of undetectable or low serum prostate-specific antigen level","volume":"109","author":"Leibovici","year":"2007","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.urolonc.2025.110987_bib0108","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.urology.2015.06.011","article-title":"Sarcomatoid carcinoma of the prostate: retrospective review of a case series from the Johns Hopkins Hospital","volume":"86","author":"Markowski","year":"2015","journal-title":"Urology"},{"issue":"10","key":"10.1016\/j.urolonc.2025.110987_bib0109","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1097\/01.pas.0000209838.92842.bf","article-title":"Sarcomatoid carcinoma of the prostate: a study of 42 cases","volume":"30","author":"Hansel","year":"2006","journal-title":"Am J Surg Pathol"},{"issue":"11","key":"10.1016\/j.urolonc.2025.110987_bib0110","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.5858\/arpa.2013-0212-RS","article-title":"Stromal tumor of uncertain malignant potential of the prostate","volume":"138","author":"Murer","year":"2014","journal-title":"Arch Pathol Lab Med"},{"issue":"5","key":"10.1016\/j.urolonc.2025.110987_bib0111","doi-asserted-by":"crossref","DOI":"10.1177\/03000605241253756","article-title":"Prostatic stromal tumor of uncertain malignant potential: a case report and literature review","volume":"52","author":"Zhu","year":"2024","journal-title":"J Int Med Res"},{"issue":"11","key":"10.1016\/j.urolonc.2025.110987_bib0112","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1038\/modpathol.2013.99","article-title":"Common chromosomal aberrations detected by array comparative genomic hybridization in specialized stromal tumors of the prostate","volume":"26","author":"Pan","year":"2013","journal-title":"Mod Pathol"},{"issue":"S1","key":"10.1016\/j.urolonc.2025.110987_bib0113","doi-asserted-by":"crossref","first-page":"S133","DOI":"10.1038\/modpathol.2017.155","article-title":"Mesenchymal tumors of the prostate","volume":"31","author":"McKenney","year":"2018","journal-title":"Mod Pathol"},{"issue":"1","key":"10.1016\/j.urolonc.2025.110987_bib0114","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.pathol.2020.09.017","article-title":"Prostatic stromal proliferations: a review","volume":"53","author":"Bostwick","year":"2021","journal-title":"Pathology"},{"issue":"4","key":"10.1016\/j.urolonc.2025.110987_bib0115","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.cell.2017.10.014","article-title":"Comprehensive and integrated Genomic characterization of adult soft tissue sarcomas","volume":"171","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.urolonc.2025.110987_bib0116","doi-asserted-by":"crossref","DOI":"10.1155\/2024\/4001796","article-title":"ATRX and its prognostic significance in soft tissue sarcoma","volume":"2024","author":"Cullen","year":"2024","journal-title":"Sarcoma"},{"issue":"10","key":"10.1016\/j.urolonc.2025.110987_bib0117","first-page":"2072","article-title":"Targeted next-generation sequencing of cancer genes identified frequent TP53 and ATRX mutations in leiomyosarcoma","volume":"7","author":"Yang","year":"2015","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.urolonc.2025.110987_bib0118","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2025.155840","article-title":"Primary sarcomas of the bladder and prostate: a genomic landscape study","volume":"267","author":"Hariri","year":"2025","journal-title":"Pathol Res Pract"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925005241?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925005241?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T11:51:45Z","timestamp":1784548305000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143925005241"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":118,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S1078143925005241"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.110987","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular pathology of rare histologic variants and treatment-resistant lineages of prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.110987","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"110987"}}